A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands

British Journal of Pharmacology

Volumn 171, Issue 14, 2014, Pages 3364-3375

  Swinney, David C ^a,b   Beavis, Paul ^a   Chuang, Kai Ting ^a   Zheng, Yue ^a   Lee, Ina ^a   Gee, Peter ^a   Deval, Jerome ^a   Rotstein, David M ^a   Dioszegi, Marianna ^a   Ravendran, Palani ^a   Zhang, Jun ^a   Sankuratri, Surya ^a   Kondru, Rama ^a   Vauquelin, Georges ^c  

^a ROCHE BIOSCIENCE   (United States)

^b Institute for Rare and Neglected Diseases Drug Discovery   (United States)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

allosteric; binding kinetics; CCR5; HIV 1 infection; maraviroc; molecular mechanism of action; pharmacology

Indexed keywords

APLAVIROC; CHEMOKINE RECEPTOR CCR5; MARAVIROC; VICRIVIROC; CCR5 PROTEIN, HUMAN; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYCLOHEXANE DERIVATIVE; LIGAND; TRIAZOLE DERIVATIVE;

ARTICLE; BINDING AFFINITY; BINDING KINETICS; CHO CELL LINE; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; MOLECULAR MECHANICS; MUTANT; PRIORITY JOURNAL; SIMULATION; WILD TYPE; ALLOSTERISM; BINDING SITE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; KINETICS; METABOLISM; STRUCTURE ACTIVITY RELATION; TIME;

ALLOSTERIC REGULATION; BINDING SITES; CCR5 RECEPTOR ANTAGONISTS; CYCLOHEXANES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KINETICS; LIGANDS; RECEPTORS, CCR5; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS; TRIAZOLES;

EID: 84903211679     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12683     Document Type: Article

References (45)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
2. Cheng Y, Prusoff WH, (1973). Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
3. Copeland R, (2010). The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety. Expert Opin Drug Discov 5: 305-310.
4. Copeland RA, (2011). Conformational adaptation in drug-target interactions and residence time. Future Med Chem 3: 1491-1501.
5. Copeland RA, Pompliano DL, Meek TD, (2006). Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 5: 730-739.
6. Del Carmine R, Molanari P, Sbraccia M, Ambrosio C, Costa T, (2004). 'Induced-fit' mechanism for catecholamine binding to the beta2-adrenergic receptor. Mol Pharmacol 66: 356-363.
7. Demarest JF, Sparks SS, Schell K, Shibayama S, McDanal CB, Fang L, et al. (2008). In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of aplaviroc. J Clin Pharmacol 48: 1179-1188.
8. Dragic T, Trkola A, Thompson DA, Cormier EG, Kajumo FA, Maxwell E, et al. (2000). A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci USA 97: 5639-5644.
9. Fano A, Ritchie W, Carrieri A, (2006). Modeling of the structural basis of human CCR5 chemokine receptor function: from homology model building and molecular dynamics validation to agonist and antagonist docking. J Chem Inf Model 46: 1223-1235.
10. Fatkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoeplman AI, et al. (2005). Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 11: 1170-1172.
11. Fierens FLP, Vanderheyden PML, De Backer J-P, Vauquelin G, (1999). Insurmountable angiotensin II AT1 receptor antagonists: the role of tight antagonist binding. Eur J Pharmacol 372: 199-206.
12. Garcia-Perez J, Rueda P, Staropoli I, Kellenberger E, Alcami J, Arenzana-Seisdedos F, et al. (2011a). New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection. J Biol Chem 286: 4978-4990.
13. Garcia-Perez J, Rueda P, Alcami J, Rognan D, Arenzana-Seisdedos F, Lagane B, et al. (2011b). Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5). J Biol Chem 286: 33409-33421.
14. Ghanouni P, Gryczynski Z, Steenhuis JJ, Lee TW, Farrens DL, Lakowicz JR, et al. (2001). Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor. J Biol Chem 276: 24433-24436.
15. Keeble AH, Kleanthous C, (2005). The kinetic basis for dual recognition in colicin endonuclease-immunity protein complexes. J Mol Biol 352: 656-671.
16. Kenakin T, Jenkinson S, Watson C, (2006). Determining the potency and molecular mechanism of action of insurmountable antagonists. J Pharmacol Exp Ther 319: 710-723.
17. Kobilka B, Schertler GF, (2008). New G-protein-coupled receptor crystal structures: insights and limitations. Trends Pharmacol Sci 29: 79-83.
18. Kobilka BK, Deupi X, (2007). Conformational complexity of G-protein-coupled receptors. Trends Pharmacol Sci 28: 397-406.
19. Kondru R, Zhang J, Ji C, Mirzadegan T, Rotstein D, Sankuratri S, et al. (2008). Molecular interactions of CCR5 with major classes of small-molecule CCR5 antagonists. Mol Pharmacol 73: 789-800.
20. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. (1996). Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86: 367-377.
21. Lu H, Tonge PJ, (2010). Drug-target residence time: critical information for lead optimization. Curr Opin Chem Biol 14: 467-474.
22. Maeda K, Das D, Ogata-Aoki H, Nakata H, Miyakawa T, Tojo Y, et al. (2006). Structural and molecular interactions of CCR5 inhibitors with CCR5. J Biol Chem 281: 12688-12698.
23. Morrison JF, Walsh CT, (1988). The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol 61: 201-301.
24. Napier C, Sale H, Mosley M, Rickett G, Dorr P, Mansfield R, et al. (2005). Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human. Biochem Pharmacol 71: 163-172.
25. Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC, et al. (2007). Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 450: 383-388.
26. Rosenbaum DM, Cherezov V, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, et al. (2007). GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science 318: 1266-1273.
27. Seibert C, Ying W, Gavrilov S, Tsamis F, Kuhmann SE, Palani A, et al. (2006). Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology 349: 41-54.
28. Strickland S, Palmer G, Massey V, (1975). Determination of dissociation constants and specific rate constants of enzyme-substrate (or protein-ligand) interactions from rapid reaction kinetic data. J Biol Chem 250: 4048-4052.
29. Swaminath G, Deupi X, Lee TW, Zhu W, Thian FS, Kolilka TS, et al. (2004). Probing the beta2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J Biol Chem 280: 22165-22171.
30. Swinney DC, (2004). Biochemical mechanisms of drug action: what does it take for success? Nat Rev Drug Discov 3: 801-808.
31. Swinney DC, (2006). Can binding kinetics translate to a clinically differentiated drug? From theory to practice. Lett Drug Des Disc 3: 569-574.
32. Swinney DC, (2009). The role of binding kinetics in therapeutically useful drug action. Curr Opin Drug Discov Devel 12: 31-39.
33. Takezako T, Gogonea C, Saad Y, Noda K, Karnik SS, (2004). Network leaning as a mechanism of insurmountable antagonism of the angiotensin II type 1 receptor by non-peptide antagonists. J Biol Chem 279: 15248-15257.
34. Tan Q, Zhu Y, Li J, Chen Z, Han GW, Kufareva I, et al. (2013). Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 341: 1387-1390.
35. Teague SJ, (2003). Implications of protein flexibility for drug discovery. Nat Rev Drug Discov 2: 527-541.
36. Tsamis F, Gavrilov S, Kajumo F, Seibert C, Kuhmann S, Ketas T, et al. (2003). Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol 77: 5201-5208.
37. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, et al. (2007). Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320: 1-13.
38. Vauquelin G, Fierens F, Verheyen I, Vanderheyden P, (2001a). Insurmountable AT1 receptor antagonism: the need for different antagonist binding states of the receptor. Trends Pharmacol Sci 22: 343-344.
39. Vauquelin G, Morsing P, Fierens FLP, De Backer JP, Vanderheyden PML, (2001b). A two-state receptor model for the interaction between angiotensin II AT1 receptors and their non-peptide antagonists. Biochem Pharmacol 61: 277-284.
40. Vauquelin G, Van Liefde I, Vanderheyden P, (2002). Models and methods for studying insurmountable antagonism. Trends Pharmacol Sci 23: 514-518.
41. Vauquelin G, Fierens F, Van Liefde I, (2006). Long-lasting AT1 receptor binding and protection by candesartan: comparison to other biphenyl-tetrazole sartans. J Hypertens 24: S23-S30.
42. Vauquelin G, Bostoen S, Vanderheyden P, Seeman P, (2012). Clozapine, atypical antipsychotics and the benefits of fast-off D2 dopamine receptor antagonism. Naunyn Schmiedebergs Arch Pharmacol 385: 337-372.
43. Watson C, Jenkinson S, Kazmierski W, Kenakin T, (2005). The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol 67: 1268-1282.
44. Wells JA, (1990). Additivity of mutational effects in proteins. Biochemistry 29: 8509-8517.
45. Yao X, Parnot C, Deupi X, Ratnala VR, Swaminath G, Farrens D, et al. (2006). Coupling ligand structure to specific conformational switches in the beta2-adrenoceptor. Nature Chem Biol 2: 417-422.